Prof Lim Tock Han is a Senior Consultant at NHG Eye Institute @ Tan Tock Seng Hospital and Group Chairman Medical Board, NHG.

He is the immediate past director of NHG Eye Institute, Tan Tock Seng Hospital, Singapore. He is also the immediate past Deputy Group CEO (Education and Research) of NHG Health, Singapore.

He was fellowship trained in Mayo Clinic, Rochester, Mn, USA. Among his clinical and research interests are Age-Related Macular Degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV). He has pioneered the use of Confocal Scanning Laser Indocyanine Angiography (CSLO-ICGA) in the region for the diagnosis and treatment of PCV, culminating in the setting up of the region’s first reading center for PCV imaging (Fundus Imaging Reading Centre, FIRC) and the EVEREST Trial (by Novartis), the first prospective randomized controlled trial of PCV. He was the founding Designated Institutional Official for the NHG-AHPL Residency Programme, one of first institution worldwide accredited by Accreditation Council for Graduate Medical Education International (ACGME-I).

He is a Clinical Associate Professor in Ophthalmology at the National University of Singapore, Division of Graduate Medical Studies. He is also Professor (Clinical Practice) Lee Kong Chian Medicine, Nanyang Technology University. He was also the founding President of the College of Ophthalmologists Academy of Medicine (Singapore).